- Nachrichtendetail
-
12.06.2024 16:25:59 - dpa-AFX: Nektar Presents Positive Preclinical Data On TNFR2 For Treatment Of Inflammatory Disease
WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR), Wednesday announced
preclinical data on tumor necrosis factor receptor 2 or TNFR2 agonist and
bivalent antibody NKTR-0165 for the treatment of inflammatory diseases.
According to the data, NKTR-0165 binds to TNFR2, a controller of inflammation,
on regulatory T cells to boost immunosuppressive functions, the company stated.
Currently, Nektar's stock is climbing 0.79 percent, to $1.27 on the Nasdaq.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
preclinical data on tumor necrosis factor receptor 2 or TNFR2 agonist and
bivalent antibody NKTR-0165 for the treatment of inflammatory diseases.
According to the data, NKTR-0165 binds to TNFR2, a controller of inflammation,
on regulatory T cells to boost immunosuppressive functions, the company stated.
Currently, Nektar's stock is climbing 0.79 percent, to $1.27 on the Nasdaq.
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Nektar Therapeutics | 165417 | NASDAQ | 1,160 | 21.06.24 23:21:21 | +0,070 | +6,42% | 1,110 | 1,150 | 1,080 | 1,160 |
